Pharmacologic analysis of non-synonymous coding h5-HT2A SNPs reveals alterations in atypical antipsychotic and agonist efficacies

Pharmacogenomics Journal

Volumn 6, Issue 1, 2006, Pages 42-51

  Davies, M A ^a   Setola, V ^a   Strachan, R T ^a   Sheffler, D J ^a   Salay, E ^a   Hufeisen, S J ^a   Roth, Bryan L ^a  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

1197V; 5 Ht2A; A447V; H452Y; Serotonin receptors; T25N

Indexed keywords

(3 CHLOROPHENYL)PIPERAZINE; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; 5 METHOXY N,N DIMETHYLTRYPTAMINE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CLOZAPINE; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN; SEROTONIN 2A RECEPTOR; TRYPTAMINE; ZIPRASIDONE;

ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SPECIFICITY; GENE SEQUENCE; GENETIC VARIABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; PHARMACOGENETICS; PRIORITY JOURNAL; RANDOMIZATION; RECEPTOR BINDING; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; STATISTICAL SIGNIFICANCE;

ANTIPSYCHOTIC AGENTS; BINDING, COMPETITIVE; CELL LINE; CLONING, MOLECULAR; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; LIGANDS; POLYMORPHISM, SINGLE NUCLEOTIDE; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN AGONISTS; TRANSFECTION;

EID: 31044447525     PISSN: 1470269X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.tpj.6500342     Document Type: Article

References (49)

1. Roth BL, Hanizavareh SM, Blum AE. Serotonin receptors represent highly favorable molecular targets for cognitive enhancement in schizophrenia and other disorders. Psychopharmacology (Berl) 2004; 174: 17-24.
2. Seeman P. Atypical antipsychotics: Mechanism of action. Can J Psychiatry 2002; 47: 27-38.
3. i values. J Pharmacol Exp Ther 1989; 251: 238-246.
4. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma Jr FJ, Shen Y et al. Binding of typical and atypical antipsychotic agents to 5-hydroxytryptamine-6 and 5-hydroxytryptamine-7 receptors. J Pharmacol Exp Ther 1994; 268: 1403-1410.
5. Roth BL, Ciaranello RD, Meltzer HY. Binding of typical and atypical antipsychotic agents to transiently expressed 5-HT1C receptors. J Pharmacol Exp Ther 1992; 260: 1361-1365.
6. Shapiro DA, Renock S, Arrington E, Chiodo LA, Liu LX, Sibley DR et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacology 2003; 28: 1400-1411.
7. Arranz MJ, Kerwin RW. Neurotransmitter-related genes and antipsychotic response: Pharmacogenetics meets psychiatric treatment. Ann Med 2000; 32: 128-133.
8. Sodhi MS, Arranz MJ, Curtis D, Ball DM, Sham P, Roberts GW et al. Association between clozapine response and allelic variation in the 5-HT2C receptor gene. Neuroreport 1995; 7: 169-172.
9. Barbee JG, Conrad EJ, Jamhour NJ. The effectiveness of olanzapine, risperidone, quetiapine, and ziprasidone as augmentation agents in treatment-resistant major depressive disorder. J Clin Psychiatry 2004; 65: 975-981.
10. Citrome L, Volavka J. The promise of atypical antipsychotics: Fewer side effects mean enhanced compliance and improved functioning. Postgrad Med 2004; 116: 49-51, 55-59, 63.
11. Malhotra AK, Murphy Jr GM, Kennedy JL. Pharmacogenetics of psychotropic drug response. Am J Psychiatry 2004; 161: 780-796.
12. Wolfgang W, Hoeg E, Lucas J, Wang D. Genetic variations in human G protein coupled receptors: Implications for drug therapy. AAPS Pharm Sci 2001; 2: 1-27.
13. Licinio J, Wong ML. Back to where it all started: Monoamines and behavior - from drug responses to genes. Mol Psychiatry 2004; 9: 427.
14. Scharfetter J. Pharmacogenetics of dopamine receptors and response to antipsychotic drugs in schizophrenia - an update. Pharmacogenomics 2004; 5: 691-698.
15. Roth BL, Sheffler DJ, Kroeze WK. Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004; 3: 353-359.
16. Nichols DE. Hallucinogens. Pharmacol Ther 2004; 101: 131-181.
17. Glennon RA, Teitler M, Sanders-Bush E. Hallucinogens and serotonergic mechanisms. NIDA Res Monogr 1992; 119: 131-135.
18. Glennon RA. Phenylalkylamine stimulants, hallucinogens, and designer drugs. NIDA Res Monogr 1991; 105: 154-160.
19. Aghajanian GK, Marek GJ. Serotonin and hallucinogens. Neuropsychopharmacology 1999; 21(2 Suppl): 16S-23S.
20. Roth BL, Berry SA, Kroeze WK, Willins DL, Kristiansen K. Serotonin 5-HT2A receptors: Molecular biology and mechanisms of regulation. Crit Rev Neurobiol 1998; 12: 319-338.
21. Kristiansen K, Kroeze WK, Willins DL, Gelber EI, Savage JE, Glennon RA et al. A highly conserved aspartic acid (Asp-155) anchors the terminal amine moiety of tryptamines and is involved in membrane targeting of the 5-HT(2A) serotonin receptor but does not participate in activation via a 'salt-bridge disruption' mechanism. J Pharmacol Exp Ther 2000; 293: 735-746.
22. Gray JA, Compton-Toth BA, Roth BL. Identification of two serine residues essential for agonist-induced 5-HT2A receptor desensitization. Biochemistry 2003; 42: 10853-10862.
23. Shapiro DA, Kristiansen K, Kroeze WK, Roth BL. Differential modes of agonist binding to 5-hydroxytryptamine(2A) serotonin receptors revealed by mutation and molecular modeling of conserved residues in transmembrane region 5. Mol Pharmacol 2000; 58: 877-886.
24. Shapiro DA, Kristiansen K, Weiner DM, Kroeze WK, Roth BL. Evidence for a model of agonist-induced activation of 5-hydroxytryptamine 2A serotonin receptors that involves the disruption of a strong ionic interaction between helices 3 and 6. J Biol Chem 2002; 277: 11441-11449.
25. Erdmann J, Shimron-Abarbanell D, Rietschel M, Albus M, Maier W, Korner J et al. Systematic screening for mutations in the human serotonin-2A (5-HT2A) receptor gene: Identification of two naturally occurring receptor variants and association analysis in schizophrenia. Hum Genet 1996; 97: 614-619.
26. Arranz MJ, Munro J, Owen MJ, Spurlock G, Sham PC, Zhao J et al. Evidence for association between polymorphisms in the promoter and coding regions of the 5-HT2A receptor gene and response to clozapine. Mol Psychiatry 1998; 3: 61-66.
27. Malhotra AK, Goldman D, Buchanan R, Breier A, Pickar D. 5HT 2a receptor T102C polymorphism and schizophrenia. Lancet 1996; 347: 1830-1831.
28. Harvey L, Reid RE, Ma C, Knight PJ, Pfeifer TA, Grigliatti TA. Human genetic variations in the 5HT2A receptor: A single nucleotide polymorphism identified with altered response to clozapine. Pharmacogenetics 2003; 13: 107-118.
29. Arranz MJ, Munro J, Sham P, Kirov G, Murray RM, Collier DA et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998; 32: 93-99.
30. Ellingrod VL, Perry PJ, Lund BC, Breer-Stille K, Fleming F, Holman TL et al. 5HT2A and 5HT2C receptor polymorphisms and predicting clinical response to olanzapine in schizophrenia. J Clin Psychopharmacol 2002; 22: 622-624.
31. Jordan S, Koprivica V, Dunn R, Tottori K, Kikuchi T, Altar CA. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur J Pharmacol 2004; 483: 45-53.
32. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002; 441: 137-140.
33. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002; 302: 381-389.
34. Cichon S, Nothen MM, Rietschel M, Propping P. Pharmacogenetics of schizophrenia. Am J Med Genet 2000; 97: 98-106.
35. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic. A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45: 789-796.
36. Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998; 19: 123-132.
37. Nothen MM, Rietschel M, Erdmann J, Oberlander H, Moller HJ, Nober D et al. Genetic variation of the 5-HT2A receptor and response to clozapine. Lancet 1995; 346: 908-909.
38. Davies MA, Sheffler DJ, Roth BL. Aripiprazole: A novel atypical antipsychotic drug with a uniquely robust pharmacology. CNS Drug Rev 2004; 10: 317-336.
39. Hazelwood LA, Sanders-Bush E. His452Tyr polymorphism in the human 5-HT2A receptor destabilizes the signaling conformation. Mol Pharmacol 2004; 66: 1293-1300.
40. Gray JA, Sheffler DJ, Bhatnagar A, Woods JA, Hufeisen SJ, Benovic JL et al. Cell-type specific effects of endocytosis inhibitors on 5-hydroxytryptamine(2A) receptor desensitization and resensitization reveal an arrestin-, GRK2-, and GRK5-independent mode of regulation in human embryonic kidney 293 cells. Mol Pharmacol 2001; 60: 1020-1030.
41. Bhatnagar A, Willins DL, Gray JA, Woods J, Benovic JL, Roth BL. The dynamin-dependent, arrestin-independent internalization of 5-hydroxytryptamine 2A (5-HT2A) serotonin receptors reveals differential sorting of arrestins and 5-HT2A receptors during endocytosis. J Biol Chem 2001; 276: 8269-8277.
42. Ozaki N, Manji H, Lubierman V, Lu SJ, Lappalainen J, Rosenthal NE et al. A naturally occurring amino acid substitution of the human serotonin 5-HT2A receptor influences amplitude and timing of intracellular calcium mobilization. J Neurochem 1997; 68: 2186-2193.
43. Reist C, Mazzanti C, Vu R, Fujimoto K, Goldman D. Inter-relationships of intermediate phenotypes for serotonin function, impulsivity, and a 5-HT2A candidate allele: His452Tyr. Mol Psychiatry 2004; 9: 871-878.
44. Bowers Jr MB, Swigar ME. Vulnerability to psychosis associated with hallucinogen use. Psychiatry Res 1983; 9: 91-97.
45. Rothman RB, Baumann MH, Savage JE, Rauser L, McBride A, Hufeisen SJ et al. Evidence for possible involvement of 5-HT(2B) receptors in the cardiac valvulopathy associated with fenfluramine and other serotonergic medications. Circulation 2000; 102: 2836-2841.
46. Chavkin C, Sud S, Jin W, Stewart J, Zjawiony JK, Siebert DJ et al. Salvinorin A, an active component of the hallucinogenic sage salvia divinorum is a highly efficacious kappa-opioid receptor agonist: structural and functional considerations. J Pharmacol Exp Ther 2004; 308: 1197-1203.
47. Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA et al. In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther 2003; 307: 138-145.
48. Christopoulos A, Parsons AM, Lew MJ, El-Fakahany EE. The assessment of antagonist potency under conditions of transient response kinetics. Eur J Pharmacol 1999; 382: 217-227.
49. Lew MJ, Angus JA. Analysis of competitive agonist-antagonist interactions by nonlinear regression. Trends Pharmacol Sci 1995; 16: 328-337.